HC Wainwright reaffirmed their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN - Free Report) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock.
DAWN has been the topic of several other reports. The Goldman Sachs Group lowered their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research report on Tuesday, March 25th. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Needham & Company LLC reissued a "buy" rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $32.29.
Get Our Latest Stock Analysis on Day One Biopharmaceuticals
Day One Biopharmaceuticals Stock Performance
Shares of Day One Biopharmaceuticals stock traded down $0.15 during trading on Thursday, hitting $6.87. 510,904 shares of the stock were exchanged, compared to its average volume of 1,100,807. Day One Biopharmaceuticals has a 12 month low of $6.65 and a 12 month high of $18.07. The stock's fifty day moving average is $10.01 and its 200 day moving average is $12.33. The stock has a market cap of $696.00 million, a PE ratio of -6.64 and a beta of -1.24.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to analysts' expectations of $27.11 million. Sell-side analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.
Insider Buying and Selling at Day One Biopharmaceuticals
In other news, CFO Charles N. York II sold 4,370 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares of the company's stock, valued at $3,021,550.48. This represents a 1.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,064 shares of company stock valued at $251,925. Corporate insiders own 8.40% of the company's stock.
Institutional Trading of Day One Biopharmaceuticals
Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $27,000. R Squared Ltd purchased a new position in Day One Biopharmaceuticals during the 4th quarter worth approximately $31,000. Tower Research Capital LLC TRC raised its stake in Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock valued at $135,000 after purchasing an additional 9,603 shares during the period. E Fund Management Co. Ltd. purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at $143,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth $150,000. 87.95% of the stock is owned by hedge funds and other institutional investors.
Day One Biopharmaceuticals Company Profile
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
